In this project, based on the information of advanced gastric/gastroesophageal junction cancer in evolution under immunotherapy combined with chemotherapy treatment, we will integrate multi-omics dynamic data to identify essential features that correlate to therapeutic effects of immunotherapy therapy, screen potential molecular markers/dominant microbiota for predicting the efficacy of immunotherapy and establish a multimodal predictive model for patients that benefit from immunotherapy. Our project could provide evidence to predict response to immunotherapy for patients with advanced gastric/gastroesophageal junction cancer and potentially optimize the clinical decision-making about therapy for advanced gastric/gastroesophageal junction cancer.
Patients with gastric or gastroesophageal junction adenocarcinoma confirmed by pathology and with advanced or metastatic disease that cannot be resected
HER2 negative
Not received any anti-tumor treatment before.
After evaluation, the treatment plan is chemotherapy combined with immunotherapy.
Patients with malignant tumors other than gastric cancer or those with tumors metastasized to the stomach from other sites.
Patients who have previously received anti-tumor treatments such as surgery, radiotherapy and chemotherapy, targeted therapy or immunotherapy.
Patients with severe infections.
Those with a history of mental illness cannot cooperate with the research.
Xiangdong Cheng
Lead sponsor
Zhejiang Cancer Hospital
Sponsor institution